Southlake, Texas, May 17, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announces it has been recognized by Healthcare Tech Outlook Magazine as a 2023 Top healthcare artificial intelligence solutions provider, highlighting the Company’s MyoVista device.
“We are honored to be recognized as one of the Healthcare Tech Outlook’s Top AI companies,” said Andrew Simpson, CEO. “We believe the evidence is now indisputable that applying artificial intelligence to the ECG will allow it to detect a much wider range of heart disease which offers the meaningful prospect of early detection and screening. Last week we announced the completion of patient enrollment for our FDA pivotal study and look forward to making an FDA submission later in the year, assuming positive results. Today, despite its limitations in detecting most forms of heart disease, millions of ECGs are performed every week. Our ultimate objective is to become a fixture in frontline healthcare to help physicians make better and earlier referral decisions for at risk patients.”
Healthcare Tech Outlook was founded to bring forth the complete picture of how the healthcare landscape can be enhanced and brought to new heights through the adoption of technology. In announcing the “Top 10 Artificial Intelligence Solutions Providers,” Healthcare Tech Outlook stated, “Artificial Intelligence (AI) is at the forefront of healthcare innovation… healthcare expenditure on AI software is predicted to increase by 40% in 2023.”
About HeartSciences
Heart Test Laboratories, Inc. d/b/a HeartSciences is a next-generation, AI electrocardiogram (AI ECG) company focused on using AI to transform the ECG (also known as the EKG) to save lives through earlier detection of heart disease. Millions of ECGs are performed every week and AI is creating a new era of opportunity for the ECG with recent AI ECG applications described as “some of the most significant advances in electrocardiography since its inception1.” The Company’s objective is to become a fixture in front-line healthcare settings to help physicians make better and earlier referral decisions for at-risk patients.
For more information, please visit: https://www.heartsciences.com. Twitter: @HeartSciences
1 – Khurram Nasir, MD, MPH, MSC,et. al., Journal of American College of Cardiology Editorial Comment Volume 76 Number 8 2020.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company’s future financial and operating performance. All statements, other than statements of historical facts, included herein are “forward-looking statements” including, among other things, statements about HeartSciences’ beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences’ filings with the U.S. Securities and Exchange Commission at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
For investor and media inquiries, please contact:
Investor Relations:
CORE IR
Scott Arnold
Email: scotta@coreir.com
Company:
Gene Gephart
Phone: +1-737-414-9213 (US)
Email: investorrelations@heartsciences.com
